Table 4.
Best Overall Response as a Predictor of Overall Survival in Men Evaluable for Pain-Response, ≥30% PSA Decline and Objective Tumor Response
| Baseline Model, n=168 | ||
|---|---|---|
| Covariate | HR (95% CI) | P |
| Mitoxantrone | Reference | – |
| Docetaxel Q3Wb | 1.10 (0.73-1.65) | 0.65 |
| Docetaxel weeklyb | 1.07 (0.72-1.59) | 0.75 |
| ≥30% PSA decline | 0.62 (0.43-0.90) | 0.012 |
| Pain response | 0.58 (0.40-0.84) | 0.004 |
| Tumor PR or CRc | 0.31 (0.11-0.94) | 0.038 |
| Tumor SDc | 0.65 (0.40-1.04) | 0.073 |
| Tumor PDc | 1.23 (0.84-1.80) | 0.3 |
| Tumor NE | Reference | – |
| 180 Day Model, n=120 | ||
| Covariate | HR (95% CI) | P |
| Mitoxantrone | Reference | – |
| Docetaxel Q3Wb | 0.86 (0.52-1.42) | 0.56 |
| Docetaxel weeklyb | 1.01 (0.62-1.63) | 0.98 |
| ≥30% PSA decline | 0.74 (0.48-1.15) | 0.18 |
| Pain response | 0.76 (0.50-1.16) | 0.21 |
| Tumor PR or CRc | 0.28 (0.09-0.85) | 0.024 |
| Tumor SDc | 0.56 (0.33-0.97) | 0.039 |
| Tumor PDc | 1.01 (0.63-1.65) | 0.95 |
| Tumor NE | Reference | – |
PSA indicates prostate-specific antigen; HR, hazard ratio; CI, confidence interval; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease; NE, not evaluable.
a
All tests included stratification for baseline Karnofsky Performance Score (KPS) and baseline pain.
b
Hazard ratio compared with mitoxantrone (adjusted for PSA, pain and radiographic response).
c
Hazard ratio compared with tumor status not evaluable.